Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

2009 • 26,132 citations

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

2009 • 15,310 citations

Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

2003 • 6,072 citations

Classification of papillomaviruses

2004 • 3,098 citations

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

2010 • 2,440 citations

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

2005 • 2,078 citations

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

2007 • 1,820 citations

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

2006 • 1,766 citations

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

2009 • 1,580 citations

The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice

2005 • 1,038 citations

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysis

2008 • 922 citations

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

2009 • 626 citations

Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence

2010 • 537 citations

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

2011 • 472 citations

Systematic review of human papillomavirus prevalence in invasive penile cancer

2008 • 402 citations

Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis

2008 • 387 citations

Health and Economic Implications of HPV Vaccination in the United States

2008 • 362 citations

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

2009 • 347 citations

Economic evaluation of human papillomavirus vaccination in the United Kingdom

2008 • 279 citations

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

2009 • 228 citations

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

2007 • 181 citations

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

2010 • 164 citations

Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR

2006 • 157 citations

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

2011 • 155 citations

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

2011 • 151 citations

Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines

2011 • 124 citations

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

2011 • 118 citations

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

2008 • 115 citations

Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty

2007 • 113 citations

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

2011 • 111 citations

HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future

2010 • 88 citations

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

2011 • 60 citations

Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles

2011 • 27 citations

Cited By (0)

No citing papers found in database